United States: The Value Of Being Highly Similar: First U.S. Biosimilar

Last Updated: April 23 2015
Article by Irena Royzman

The Biologics Price Competition and Innovation Act of 2009 (BPCIA) was passed as part of health reform, the Affordable Care Act, signed into law by President Barack Obama in March 2010. The BPCIA created an abbreviated regulatory pathway for marketing approval of biologic medicinal products that are ''biosimilar'' to an already approved product. On March 6, the Food and Drug Administration (FDA) approved the first biosimilar in U.S. history—Sandoz's biosimilar of Amgen's blockbuster drug used to prevent infections in cancer patients, Neupogen. Sandoz, a Novartis company, reaped tremendous savings in cost and time by taking advantage of the new biosimilar pathway rather than submitting a full biologics license application (BLA) to the FDA and undertaking all the studies that Amgen had to perform to obtain approval for Neupogen. The extent to which these savings will be passed on to the U.S. health care system as envisioned by the Obama administration, however, is less clear.

Biologic medicines, also known as biologics, are complex molecules that are made in living cells rather than chemically synthesized, as are the more familiar pharmaceutical products known as chemical or smallmolecule drugs. Because biologics are made in living cells, they, at most, can be similar to already approved biologics and are governed by a separate regulatory scheme than small-molecule drugs. The BPCIA permits a biosimilar maker to rely on the safety and effectiveness of the already approved biologic product, enabling a biosimilar product to gain FDA approval based on less than a full complement of preclinical and clinical data.

Landmark Year for Biosimilars in U.S.

After a slow start for the biosimilar pathway, 2015 has been a landmark year. The FDA approved Sandoz's Neupogen biosimilar, to be sold under the trade name Zarxio. Sandoz's product has been sold in the European market under the trade name Zarzio since 2009, when the European Medicines Agency (EMA) approved it as a biosimilar to Amgen's Neupogen and allowed it to be marketed for all the same medical uses as Neupogen. Since 2013, just four years after Sandoz's Zarzio became available to patients across Europe, Zarzio overtook Amgen's Neupogen as the market leader.

As in Europe, the FDA approved Zarxio for all of Neupogen's medical uses, even though Sandoz had conducted clinical trials for only one of them. The approval and its scope are not surprising. Neupogen is one of the simplest biologics on the market, making it easier to achieve biosimilarity. Sandoz's product has been sold in more than 40 countries worldwide, leading to more than 7 million patient exposure days to the product. After reviewing Sandoz's submission, the FDA concluded earlier this year that Zarxio is a biosimilar of Neupogen, i.e., that it is ''highly similar'' to Amgen's Neupogen with ''no clinically meaningful differences'' between Zarxio and Neupogen ''in terms of the safety, purity, and potency of the product.''

The FDA determined that it was scientifically justified to extrapolate the clinical data submitted by Sandoz for one indication to all five of Neupogen's indications. The potential for extrapolation is a key advantage of the biosimilar pathway as it shortcuts the need for clinical trials for each indication and therefore significantly reduces the time and expense of approval. It took Amgen an additional seven years and extensive clinical trials to obtain all five of Neupogen's indications after the FDA first approved Neupogen for one of them in 1991.

Different Story for Teva's Granix

Zarxio will not be the first version of Amgen's Neupogen in the U.S. Teva has sold a version of Amgen's Neupogen, under the trade name Granix, since 2013 after obtaining FDA approval through the submission of a full biologics license application. Teva has obtained about 14 percent of the Neupogen market after reducing the price of Granix by approximately 20 percent compared to Neupogen. The annual cost for a Granix 10-dose package was approximately 20 percent lower compared with the 10-dose package of Neupogen prefilled syringes or vials ($3,525 versus $4,939 and $4,659, respectively).

Teva submitted its regulatory application for Granix in December 2009, shortly before the BPCIA was enacted. Because Teva, unlike Sandoz, did not go through the biosimilar pathway, it could not rely on Amgen's clinical studies and obtained approval for only one of five of Neupogen's indications—the only one for which Teva provided clinical studies to the FDA. In Europe, by contrast, Teva sells the same product as a biosimilar of Amgen's Neupogen. The EMA granted Teva's biosimilar product all the same medical uses as for Neupogen in 2008. Teva may have been able sell Granix as a biosimilar in the U.S. if it waited for the BPCIA to become law before submitting its regulatory application to FDA.

In addition to not obtaining all the indications for Neupogen, Teva, unlike Sandoz, is not able to market its product as highly similar, i.e., a biosimilar, to Neupogen. Medicare reimbursement also is more favorable to Sandoz's biosimilar product than Teva's Granix.

Reimbursement, Pricing Variations

To encourage physicians to prescribe biosimilar products, the Affordable Care Act sets the reimbursement of biosimilar drugs as their average selling price plus 6 percent of the innovator drug's average selling price. This reimbursement scheme provides physicians with the same margin, 6 percent of the innovator drug's average selling price, regardless of whether the physician administers the innovator or the biosimilar product. The value of reimbursement for Zarxio therefore will be its average selling price plus 6 percent of Amgen's price for Neupogen. Because Teva's Granix was not approved through the biosimilar pathway, its reimbursement is calculated as its average selling price plus 6 percent of its own price, which is approximately 20 percent less than that for Amgen's Neupogen. Physicians therefore would obtain a greater margin from prescribing Sandoz's Zarxio than Teva's Granix. In addition, because a Zarxio-specific average selling price would not be available for up to two quarters after launch, payers can choose to set the level of reimbursement for Zarxio at the same level as Amgen's Neupogen during that time.

Given the many advantages of proceeding through the biosimilar pathway, it is perhaps surprising that when Sandoz's Global Head of Development for Biopharmaceuticals and Oncology Injectables, Mark Mc- Manish, was asked at the FDA's Advisory Committee meeting how Sandoz planned to price its product, he could not confirm that Sandoz would price below Amgen's price for Neupogen ''because in some situation[s], the price will be at parity.'' Thus, while it is clear that the biosimilar pathway offers tremendous benefits to biosimilar manufacturers, the reports on the first U.S. biosimilar raise the question as to the extent to which those savings will be passed down to the U.S. health care system.

In Europe, by contrast, Sandoz's Neupogen biosimilar has been reported to provide approximately a 25 percent to 30 percent cost-saving over Neupogen and Sandoz's product is the market leader. The same ultimately may be the case in the U.S. even if Sandoz initially prices Zarxio at parity with Amgen's Neupogen. But the competitive landscape is different in Europe than in the U.S. In Europe, Teva's biosimilar to Neupogen was approved first and was approved for all of Neupogen's medical uses. In the U.S., Teva's Granix is first but Sandoz's Zarxio is the first biosimilar and the only product approved for all of Neupogen's medical uses. In addition, the U.S. and Europe differ in reimbursement practices and incentives. As a result, the extent to which the cost-savings seen in Europe provide a precedent that is applicable to the U.S. is far from clear.

Litigation May Control Zarxio Release Timing

It also is not clear when Zarxio will reach the market and whether it will reap the advantage of being the first biosimilar of Neupogen to be approved in the U.S. The timing will depend on Amgen's lawsuit against Sandoz for violating the BPCIA, while taking advantage of Amgen's extensive preclinical and clinical data to obtain regulatory approval. Amgen is seeking to prevent Zarxio from entering the market until Sandoz complies with the BPCIA's litigation procedures and until all patent disputes are resolved. A federal court in California heard Amgen's arguments on March 13 but denied Amgen's request for an injunction against Sandoz. Amgen appealed the district court decision to the Federal Circuit on March 25 and is seeking an injunction while the appeal is pending.

Given the importance of the case, Amgen and Sandoz agreed to expedite appellate briefing and to request an early date for oral argument, potentially as soon as the Federal Circuit's June calendar. Sandoz is not launching Zarxio in the meanwhile. It has agreed not to enter the market until May 11, 2015, or a decision by the Federal Circuit on Amgen's request for an injunction pending appeal, whichever comes sooner. The timing of market entry determines whether Zarxio will be the first biosimilar on sale in the U.S. or lose the competitive advantage of being first since the FDA is already reviewing a second potential biosimilar of Neupogen, Apotex's version, and Apotex's product may be approved later this year. The FDA also is reviewing Apotex's potential biosimilar of Amgen's Neulasta, a longacting version of Neupogen, and it may be approved later this year as well.

Previously published in Life Sciences Law & Industry Report, 9 LSLR 459, 04/17/2015.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

*** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.